208 related articles for article (PubMed ID: 27177756)
1. Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.
Lee D; Porter J; Hertel N; Hatswell AJ; Briggs A
BioDrugs; 2016 Aug; 30(4):307-19. PubMed ID: 27177756
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C
Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718
[TBL] [Abstract][Full Text] [Related]
3. Drug treatment for melanoma: progress, but who pays?
Kefford RF
Med J Aust; 2012 Aug; 197(4):198-9. PubMed ID: 22900855
[No Abstract] [Full Text] [Related]
4. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
Chapman PB; Robert C; Larkin J; Haanen JB; Ribas A; Hogg D; Hamid O; Ascierto PA; Testori A; Lorigan PC; Dummer R; Sosman JA; Flaherty KT; Chang I; Coleman S; Caro I; Hauschild A; McArthur GA
Ann Oncol; 2017 Oct; 28(10):2581-2587. PubMed ID: 28961848
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns in advanced melanoma: findings from a survey of European oncologists.
Jones C; Zhao Z; Barber B; Bagijn M; Corrie P; Saltman D
Eur J Cancer Care (Engl); 2015 Nov; 24(6):862-6. PubMed ID: 25988349
[TBL] [Abstract][Full Text] [Related]
6. Novel targets in the treatment of advanced melanoma: new first-line treatment options.
Culos KA; Cuellar S
Ann Pharmacother; 2013 Apr; 47(4):519-26. PubMed ID: 23548648
[TBL] [Abstract][Full Text] [Related]
7. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.
Bohensky MA; Pasupathi K; Gorelik A; Kim H; Harrison JP; Liew D
Value Health; 2016 Dec; 19(8):1009-1015. PubMed ID: 27987627
[TBL] [Abstract][Full Text] [Related]
8. Comparative healthcare costs in patients with metastatic melanoma in the USA.
Chang CL; Schabert VF; Munakata J; Donga P; Abhyankar S; Reyes CM; Yim YM
Melanoma Res; 2015 Aug; 25(4):312-20. PubMed ID: 25882026
[TBL] [Abstract][Full Text] [Related]
9. Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.
Pike E; Hamidi V; Saeterdal I; Odgaard-Jensen J; Klemp M
BMJ Open; 2017 Aug; 7(8):e014880. PubMed ID: 28827234
[TBL] [Abstract][Full Text] [Related]
10. Upcoming strategies for the treatment of metastatic melanoma.
Spagnolo F; Queirolo P
Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
Heakal Y; Kester M; Savage S
Ann Pharmacother; 2011 Nov; 45(11):1399-405. PubMed ID: 22028422
[TBL] [Abstract][Full Text] [Related]
12. Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma.
Quinn C; Ma Q; Kudlac A; Palmer S; Barber B; Zhao Z
Adv Ther; 2016 Apr; 33(4):643-57. PubMed ID: 26979173
[TBL] [Abstract][Full Text] [Related]
13. Current systemic therapies for melanoma.
Palathinkal DM; Sharma TR; Koon HB; Bordeaux JS
Dermatol Surg; 2014 Sep; 40(9):948-63. PubMed ID: 25072125
[TBL] [Abstract][Full Text] [Related]
14. [Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
Koprowska K; Czyż M
Postepy Hig Med Dosw (Online); 2011 Nov; 65():734-51. PubMed ID: 22173438
[TBL] [Abstract][Full Text] [Related]
15. Vemurafenib and ipilimumab: new agents for metastatic melanoma.
Banaszynski M; Kolesar JM
Am J Health Syst Pharm; 2013 Jul; 70(14):1205-10. PubMed ID: 23820456
[TBL] [Abstract][Full Text] [Related]
16. Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
Ma Q; Chen YJ; Hines DM; Munakata J; Batty N; Barber BL; Zhao Z
J Dermatolog Treat; 2017 Sep; 28(6):549-553. PubMed ID: 28100090
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.
Barzey V; Atkins MB; Garrison LP; Asukai Y; Kotapati S; Penrod JR
J Med Econ; 2013; 16(2):202-12. PubMed ID: 23057750
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
19. A Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials.
Xie T; Huang CY; Kang X; Luo JS; Qin XM; Han F
J Cell Biochem; 2018 Jan; 119(1):640-649. PubMed ID: 28628251
[TBL] [Abstract][Full Text] [Related]
20. Accounting for Cured Patients in Cost-Effectiveness Analysis.
Othus M; Bansal A; Koepl L; Wagner S; Ramsey S
Value Health; 2017 Apr; 20(4):705-709. PubMed ID: 28408015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
